• Polyrizon initiates trial of Nasarix (PL-14) intranasal allergen blocker for seasonal allergic rhinitis

  Polyrizon has announced the initiation of its first clinical trial, a study of its Nasarix (PL-14) hydrogel nasal spray in patients with seasonal allergic rhinitis. In September 2025, the company said that it had submitted… [Read more . . .]

• Bespak and Upperton team up to offer nasal drug development and manufacturing services

  OINDP specialist CDMOs Bespak and Upperton have announced a new strategic collaboration that will offer services based on Upperton’s UpperNose nasal development platform and manufacturing capability in conjunction with Bespak nasal delivery devices. The announcement… [Read more . . .]

• FDA accepts Insmed’s sNDA to expand the use of Arikayce amikacin liposome inhalation suspension for MAC lung disease

  Insmed announced that the FDA has accepted the company’s sNDA to expand the use of Arikayce amikacin liposome inhalation suspension for the treatment of Mycobacterium avium complex (MAC) lung disease. Arikayce is delivered by PARI‘s Lamira nebulizer. According to… [Read more . . .]

• SpliSense initiates Phase 2b trial of SPL84 inhaled antisense oligonucleotide for the treatment of cystic fibrosis

  SpliSense announced that it has initiated the Phase 2b portion of the SPL84-02 trial of the SPL84 inhaled antisense oligonucleotide in CF patients with the 3849+10kb C→T splicing mutation in the CFTR gene. The Phase… [Read more . . .]

• FDA clears IND for Phase 1b trial of SMSbiotech’s inhaled stem cell therapy in patients with COPD

  California-based SMSbiotech announced that the FDA has cleared its IND for a Phase 1b trial of its inhaled small mobile stem (SMS) cell therapy in patients with COPD and that the company intends to initiate… [Read more . . .]

• Ritedose Corporation names Carolyn Berg as VP of Strategic Growth

• FDA approves Aurobindo’s generic beclomethasone MDI

• Zeteo Biomedical announces the launch of its new AriesMR active DPI

• Agomab reports results from Phase 1 study of AGMB-447 inhaled ALK5 inhibitor

• Cystic Fibrosis Foundation to make strategic investment of up to $7.3 million in Ride Therapeutics to support development of inhaled genetic therapies for CF

More news . . .